Acadia Pharmaceuticals' Rebranding and AI Integration
Acadia Pharmaceuticals' CEO, Catherine Owen Adams, discusses the company's recent rebranding and expansion into rare disease marketing, highlighting the role of AI in their strategy.
As a neurological biotech, Acadia Pharmaceuticals has rolled out a rebrand to further expand into the rare disease space, with AI playing a significant role in their marketing approach.
Acadia CEO Catherine Owen Adams shares insights on the company's rebrand, rare disease expansion, and AI integration in commercialization and marketing.
- Rebranding to expand into rare disease space
- AI's major role in marketing strategy
- Benefits and challenges of marketing as a smaller biotech
Adams draws on her marketing background to steer the company into 2026, navigating the opportunities and challenges of being a smaller biotech in the industry.
Author's summary: Acadia Pharmaceuticals rebrands and expands into rare diseases, leveraging AI in marketing.